Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Aurora Cannabis CEO says open to more M&A deals after upbeat Q2

Published 02/10/2023, 12:25 PM
Updated 02/10/2023, 01:01 PM
© Reuters. FILE PHOTO: The Logo for Aurora Cannabis Inc., a Canadian licensed cannabis producer, is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., January 8, 2019. REUTERS/Brendan McDermid

© Reuters. FILE PHOTO: The Logo for Aurora Cannabis Inc., a Canadian licensed cannabis producer, is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., January 8, 2019. REUTERS/Brendan McDermid

By Ankit Kumar

(Reuters) - Canada's Aurora Cannabis (NASDAQ:ACB) Inc would be open to undertake more merger and acquisition deals in the future to expand its medical cannabis business, the company's chief executive said on Friday.

The upbeat comments followed the cannabis producer's surprise second-quarter core profit, helped by cost saving measures it had been taking since early 2020. 

"The net cash position gives us the opportunity to do M&A," CEO Miguel Martin told Reuters in an interview.

The company will likely focus on acquiring medical assets or medical infrastructure – "something that's additive to medical would be more interesting to us than maybe others," he added.

In its earnings release late on Thursday, Aurora said it has about C$310 million ($232 million) of cash, including C$65 million of restricted cash as of Feb. 8.

In August last year, the company acquired a controlling interest in agricultural company Bevo Agtech for C$45 million.

"I think the type of M&A we would do would be consistent with what you saw with Bevo, predictable profitable… steady business," Martin said.

© Reuters. FILE PHOTO: The Logo for Aurora Cannabis Inc., a Canadian licensed cannabis producer, is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., January 8, 2019. REUTERS/Brendan McDermid

The company which draws majority of its sales from its medical cannabis business, posted an adjusted core profit of C$1.4 million compared with analysts' expectations of core loss of C$3.9 million. 

(This story has been corrected to change the currency to the Canadian dollar from the U.S. dollar in paragraph 5)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.